A U.K. competition watchdog said on June 18 that Illumina’s planned $1.2 billion acquisition of Pacific Biosciences raises anti-competitive concerns, at a minimum delaying the deal.
Ultragenyx paid San Diego’s Arcturus Therapeutics $6 million in cash and is poised to invest $24 million in the company following an expanded research agreement.
BIOTECH: Antibody Was Isolated in Lab
MappBio — a once-little known San Diego biotech that captured worldwide interest with experimental drugs for Ebola and other viruses — landed another big contract.
HEALTH CARE: Reimbursement Codes Open Door for Revenue
The mental health system is often called broken or fragmented. That’s created an opening for San Diego tech companies.
A U.K. court today ruled that Roche subsidiary Ariosa Diagnostics infringed on an Illumina prenatal testing patent, the latest in the legal saga between the two companies.
CV Sciences’ CBD oil will be sold in 945 Kroger-owned stores across 17 states, it was recently announced.
Investors Said Going Public Would Bring Increase in Investments
For biotechs, what’s the path to an initial public offering like? The CEOs of San Diego companies that took the IPO plunge weighed in on this question and others during a recent Biocom panel.
Joan Herman was recently named to the board of Carlsbad’s Ionis Pharmaceuticals.
Oncternal Retains CEO, Will Remain In San Diego
On the heels of auspicious clinical trial results, San Diego-based Oncternal Therapeutics completed a reverse merger with Tennessee’s GTx, it was announced June 10.
No New Treatments for Targeted Condition in More Than a Decade
La Jolla Pharmaceutical’s stock recently jumped after its drug candidate for regulating iron overload showed promise in preliminary clinical trial results.
Co.to Operate as Brickell, Focus on Skin Conditions
After pulling the plug on a herpes vaccine program, San Diego-based Vical is set to merge with Colorado’s Brickell Biotech in an all-stock deal.
Average Wage Is $115,000; Economic Impact Put at $39B
Employment in San Diego’s life sciences industry increased 12.5% from 2013 to 2018, states a new report.
After securing $30 million in a private stock placement in April, Evofem on June 10 closed a second tranche of $50 million.
UC San Diego Health opened an Encinitas facility as part of a bid to expand beyond hospital walls.
ER Visits Rose 18% from 2012 to 2017, posing financial and operational difficulties
In 2013, Scripps Mercy Hospital’s emergency department doubled in size after a multiphase revamp. Six years later, Scripps officials said demand caught up.
La Jolla Pharmaceutical’s drug candidate for regulating iron overload showed promise in interim clinical trial data, sending the company’s stock soaring.
Philadelphia-based PCI Pharma Services will open a third San Diego site, the company recently announced.
Pharma: Analyst Says Main Targets Must Be Hit
Tocagen recently reported that a clinical trial of its brain cancer drug candidate will continue after an interim analysis. Afterward,its stock fell sharply, but company analysts were still mostly optimistic that the San Diego drug maker will deliver.
Jeff Settleman on June 5 was named Pfizer’s group head of oncology and research development.
La Jolla-based Inhibrx on June 3 filed for a $74.75 million initial public offering to advance three cancer drugs in clinical trials and other programs.
San Ysidro Health has taken steps to acquire Mountain Health, another nonprofit that provides health care services to low-income San Diegans.
A global effort to combat viral threats like Ebola that’s headed by a San Diego professor has been awarded up to $35 million.
Solana Beach-based Scientist.com built an online marketplace for startups linked to 5AM Ventures that allows the early-stage firms to put specialty biotech services out to bid.
Cibus – which uses gene editing to increase crop yields – called off its initial public offering, according to recently filed paperwork.
La Jolla-based Inhibrx recently took in a $40 million investment from Viking Global Investors to advance a pipeline targeting cancer, infectious disease and orphan diseases.
BIOTECH: Contraceptive Gel Is Part of CEO's Health Mission for Women
Evofem Biosciences wants to be the next big thing in birth control. After a long road, the San Diego biotech finds itself in a pivotal stretch.
PROPERTY: Tenant Demand Still Robust; Rents Increase
San Diego’s life sciences cluster produced only 77,600 square feet of occupancy growth in the first quarter of the year.
LEGAL: Ra’s Lawsuit Centers On IPO
Carlsbad’s Ra Medical Systems is alleging a rival interfered with its initial public offering.
BIOTECH: BioNTech Plans to Establish a Local Research Facility
The recent acquisition of San Diego’s MabVax has been a long time coming. MabVax sold its cancer drug assets and its lab equipment to German company BioNTech, it was announced earlier this month.
San Diego’s Trovagene will partner with Nektar Therapeutics to explore combining their two drug candidates to treat metastatic colon cancer.
Locana, a San Diego biotech that repurposed the gene-editing system CRISPR, has raised a $55 million series A round.
San Diego’s Reneo Pharmaceuticals raised a $50 million Series A round to tackle metabolism and energy disorders.
HEALTH: Arm of Moores Cancer Center Holds Annual Symposium
A department at UC San Diego Health’s Moores Cancer Center is known for putting on a symposium to translate groundbreaking oncology discoveries into therapeutics.
PHARMA: Acquisitions Part of CRO Consolidation Trend Locally, Nationwide
WuXi AppTec is making moves in San Diego. The Chinese pharmaceutical company earlier this month bought San Diego-based Pharmapace.
HEALTH: Hospitals Grapple With Use, Costs and Concerns
Rady Children’s Hospital holds a world record for fastest genomic diagnosis. Instrumental in the feat: artificial intelligence.
M&A: Co. Will Operate as Armata Pharmaceuticals
Two companies, new name. San Diego-based AmpliPhi Biosciences and Marina del Rey’s C3J Therapeutics have merged, operating as Armata Pharmaceuticals, focused on antibiotic-resistant infections.
Carlsbad’s Ra Medical Systems on May 16 sued Strata Skin Sciences and its board chair. The lawsuit alleges a campaign of false and misleading statements to financial partners before, during and after Ra Medical’s initial public offering.
BIOTECH: Co. Gets Licensing Fee From Argenx
San Diego-based Halozyme reported higher revenue and net income in first quarter results, thanks to the company’s platform technology. Looking forward, the company is heading for an inflection point.
Carlsbad-based Vertiflex – maker of a device that reduces spine pressure – was acquired by Boston Scientific. The deal includes Boston Scientific paying $465 million upfront, with additional payments dependent on commercial milestones over the next three years.
medicine: Costs To Scale Up Leave Some Cos. in the Red
The heavy-hitters of San Diego medtech — Dexcom, ResMed, Tandem Diabetes Care and NuVasive — saw revenue either rise or shoot up in recent quarterly results.
A drug candidate from Poseida Therapeutics aimed at relapsed multiple myeloma has picked up an orphan drug designation.
Genomics titan Illumina has filed a patent infringement lawsuit against a BGI Group subsidiary.
life science: Also On the Move, BioLegend Claims Entire Street
Two biotechs, Takeda Pharmaceutical Co. and BioLegend, recently opened new campuses in San Diego.
HEALTH CARE: Florida Firm Gives It Telehealth Capabilities
AMN Healthcare’s recently announced acquisition will expand its footprint in fast-growing markets, while positioning the nation’s largest health staffing firm for what could be the wave of the future.
Wuxi Apptec earlier this month bought San Diego-based Pharmapace, the latest in consolidation among niche players in the drug development market.
Researchers at UC San Diego were awarded $4.7 million in grants to identify therapeutics and improve surgery for Chrohn’s disease.
San Diego-based MabVax Therapeutics sold its cancer drug assets and its lab equipment to BioNTech, it was announced May 8.
San Diego-based Halozyme reported $56.9 million in first quarter revenue, an 84 percent year-over-year increase.
In search of therapies for brain diseases, Lunbeck will pay $250 million upfront to buy San Diego-based Abide Therapeutics.
In first quarter results, Acadia Pharmaceuticals recorded an $85.3 million operating loss due to the company spending more on clinical research and marketing.